No abstract

Historically, purified human-and bovine serum albumin have been widely used as key components in the supplementation of serum-free media (SFM) (Simula and Grosvenor 2009). Albumin has numerous biological functions including its role as an important carrier of serum-derived substances that support mammalian cell growth, in binding and delivering molecules to the cell, and as an antioxidant. At industrial scale, albumin is used as a multifunctional protein to control and optimize certain cell culture parameters such as supporting cell viability when cells are under both physical and metabolic stress. Recently developed and launched to the market in 2009, is an animal-free (AF) recombinant albumin, CellPrime TM rAlbumin AF-G (rAlbumin). It is designed for industrial cell culture to enhance cellular performance and increase the safety profile of biopharmaceutical production processes. Expressed in Aspergillus oryzae, rAlbumin is a purified and well characterized supplement, providing all the benefits of albumin without the regulatory risks and challenges associated with serum-derived albumin. In this study, we evaluate rAlbumin for its ability to enhance cellular performance in CHO cells, using a mini-bioreactor platform and compare its performance to that achieved with bovine serum albumin (BSA). The results indicate that key cell culture performance parameters (viability, growth, apoptosis, and productivity) are significantly improved in the presence of rAlbumin in a chemically defined (CD) commercially available media formulation and are equivalent or enhanced when compared to BSA.

No abstract

No abstract